Clinical Drug Development Articles & Analysis
13 articles found
Recombinant protein drugs refer to protein products that originate from animals and plants and are developed through biotechnology research. ...
Medical advancement relies on clinical trials, which are essential for the development of safe and effective innovative treatments. However, the success and general applicability of these treatments heavily depend on the diversity of the participants involved¹?³. This blog explores the importance of achieving data diversity in clinical trials to enhance clinical trial results and ...
They have the advantages of small size, high stability, and good penetration, and therefore have a wide range of application prospects in the fields of clinical treatment, diagnostic reagent development, etc.Characteristics of NanobodiesThe size of nanobodies usually ranges between 10-15kDa, which is only 1/10 of the size of regular antibodies. ...
Therefore, nanobodies have shown good control effects in disease diagnosis, cancer and infectious diseases.What are Nanobody-Drug Conjugates (NDCs)The development concept of nanobody-drug conjugates (NDCs) is similar to that of antibody drug conjugates (ADC), that is, the antibody in ADC is replaced by a nanobody with higher ...
Animal models play a critical role in biomedical research, as they allow scientists to study complex disease processes, develop new therapies, and test their safety and efficacy before moving into human clinical trials. ...
Effective and Efficient Drug Development Challenge Increased Cost, Risk, and Competition in the Drug Development Processes Dr. ...
ByStatsol
With the emergence of COVID-19, Decentralisation of Clinical Trials became necessary to comply with social distancing requirements while carrying out clinical research. Over the past few years, the clinical trial landscape has shifted its focus to patient-centric practices to promote patient engagement. But now as the pandemic is long gone, it is time to reflect on how DCT studies are genuinely ...
ByClinion
The Clinical CRISPR Successes Are Stacking Up. But Where’s the Emphasis on Quality Control? ...
When promising drug candidates are identified for further investigation in clinical trials, sponsor companies are usually optimistic about outcomes. But there are times, when after years of sunk effort and resources, clinical trials fail to bring a viable drug to market. Frequently, a drug fails for safety or ...
The Dana-Farber Cancer Institute utilized SWOT analysis to targeted protein degradation drug development to better evaluate the approach's strengths, weaknesses, opportunities, and threats. ...
Published by Vijay K Singh and Thomas M Seed on September 3, 2021, in Expert Opinion on Drug Discovery and deals with the necessity of animal models for modern drug research in the direction of animal strains, animal models, requirements, and pathways for developing new drugs. ...
Symberix co-founder Matt Redinbo also published a research article in PNAS in March 2020 describing microbiota-targeted therapeutics that inhibit gut bacterial β-glucuronidases to enhance anticancer drug efficacy. Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to ...
Symberix is developing bacteria-targeted small molecules that prevent the GI toxicity of many common medications, including nonsteroidal anti-inflammatory drugs and irinotecan. ...